Background: Bladder cancer cells illustrate major disruptions in their DNA methylation patterns as compared with normal ones. Authors aimed to identify epigenetic molecular markers in urine for early detection of bladder cancer.
Introduction
Bladder cancer is a global problem, the highest frequency of bladder cancer worldwide is observed in Egypt, this high incidence is believed to be due to endemic infestation by Schistosoma haematobium (1, 2) .
The gold standard for bladder cancer detection remains to be cystoscopy. Not only this technique is invasive, but also 10% to 40% of malignancies may be undetected by this procedure (3) . Alternatively, urine cytology is known for its good specificity but poor sensitivity for early stages and low grades. An array of urine markers were evaluated to improve the diagnostic ability of urine cytology and, perhaps, to reduce the need for frequent cystoscopies during follow-up, especially in those with low-risk disease (4) (5) (6) (7) (8) (9) (10) (11) .
Promoter hypermethylation of CpG islands is strongly associated with tumor development and survival in bladder carcinogenesis (1) . Several reports indicate that body fluids, including urine can be used for noninvasive detection of bladder cancer by hypermethylation of DNA (12, 13) .
The aim of this study was to evaluate the usefulness of 2 methylated genes: RARb 2 and APC as urine markers to detect bladder cancer in urine sediments, especially those with bilharzial infestation in comparison to urine cytology.
Materials and Methods

Clinical samples
This study was approved by the Medical Ethical Committee of the Ain Shams University, Faculty of Medicine, (14, 15) .
Collection of samples
Sera (5 mL) and voided urine (30-60 mL) samples were obtained from all individuals before they received any treatment and before they underwent surgery. Each urine sample was centrifuged and then the urinary sediment was washed with PBS. A portion of the pellet was used for cytological and microscopic examinations (16) and the other portion was treated with protease inhibitor cocktail (8) and stored at À80 C for further processing to extract DNA to be used for detection of methylated APC and RARb 2 .
Detection of schistosomiasis antibodies in serum
The sera were used for detection of schistosomiasis antibodies by using the Cellognost Schistosomiasis H Kit (Dade Behring Marburg GmbH; ref. 17 ).
Detection of methylated RARb 2 and APC genes
This was accomplished blindly in all samples malignant, benign, and control in 4 phases. In the first phase, DNA was extracted from urine pellets. In the second phase, DNA was treated by bisulfite. In the third phase, we amplified the gene by PCR. Finally, the fourth phase included detection of the PCR products.
DNA isolation from urine pellets. DNA extraction was done by using AllPrep DNA/RNA Micro kit (QIAGEN Ltd). DNA integrity was checked by 2% agarose electrophoresis and 2 samples with degraded DNA were discarded.
DNA modification. The bisulfite modification was done by using the EZ DNA Methylation Kit (Zymo Research) as follows: 130 mL CT conversion reagent was added to 20 mL of purified DNA sample in a PCR tube. Then PCR tubes were placed in Hybaid Thermal Cycler (Thermo Electron) and temperature conditions were as follows: 98 C for 10 minutes; 64 C for 2.5 hours; and storage at 4 C overnight. Then the modified DNA was loaded into Zymo-Spin IC Column after addition of 600 mL of M-binding buffer. After centrifugation at full speed for 30 seconds, the flow-through was discarded, and 100 mL of the M-wash buffer were added to the column and centrifuged at full speed for 30 seconds. Then 200 mL of M-desulfonation buffer were added to the column and incubated at room temperature for 20 minutes, followed by centrifugation at full speed for 30 seconds. Two hundred microliters of M-wash buffer were added twice to the column and after each time, centrifugation at high speed for 30 minutes was done. At the end of the procedure, DNA was eluted after the addition of 10 mL elution buffer and stored at À20 C for methylation-specific PCR (MSP).
MSP of RARb 2 and APC genes. MSP of RARb 2 . Amplification of the RARb 2 gene region of the modified DNA samples was first done by an outer PCR reaction by using external primers for RARb 2 gene (18) . The amplified products of this PCR were used as DNA templates in the nested PCR. The reaction was conducted by using puReTaq Ready-To-Go PCR beads (GE Healthcare), in brief: a 635-bp region, encomposing 27 RARb 2 CpG sites in the RARb 2 regulatory region was amplified by using first primer set [RARb 2 sense 5\-TTA AGT TTT GTG AGA ATT TTG-3\ and set (19) . PCR was done by using HotStarTaq Master Mix Kit (provided by QIAGEN) and done for 39 cycles consisting of denaturation at 94 C for 1 minute, annealing at 54 C for 1 minute, and extension at 72 C for 1 minute and hold at 4 C. Detection of PCR products. Agarose gel electrophoresis (2%) was used to separate DNA fragments on the basis of size and visualized by ethidium bromide staining as previously described (20) . The PCR products were compared with molecular weight marker (provided by Promega, GE Healthcare Bio-science, UK limited) by using Gel-pro (version 3.1; Media cybernetics) software.
Methylated and unmethylated RARb 2 appear as bands at 146 bp, respectively (Fig. 1A) , whereas methylated and unmethylated APC appears as bands at 98 bp and 108 bp, respectively (Fig. 1B) .
Statistical analysis
Univariate analyses were done by using a c 2 square test. Significant markers by univariate analysis were further tested by multivariate analysis using general linear model. Efficacies of investigated markers were calculated according to standard statistical methods (21) . All analyses were done using Statistical Package for the Social Sciences software (SPSS Inc.).
Results
A total of 320 participants were included in this study. Two hundred and ten were diagnosed with bladder cancer; 128 of them were bilharzial bladder cancer and the remaining (n ¼ 82) were nonbilharzial bladder cancer. Among the 61 patients diagnosed with benign urological diseases, 28 showed benign bilharzial lesions (18 with bilharzial dysplasia, 10 with bilharzial cystitis), and the rest (n ¼ 33) were nonbilharzial lesions (17 with renal stones, 9 with bladder polyp, and 7 with pyelonephritis). All healthy volunteers (n ¼ 49) were nonbilharzial. Clinicopathologic and demographic characteristics of bladder cancer group are shown in Table 1 .
Distribution of RARb 2 and APC methylation patterns among the studied groups Methylated RARb 2 was detected in 62.8% malignant group and 16.4% benign group, and it was not detected in normal individuals (c 2 ¼ 64, P ¼ 0.009). Similarly, methylated APC promoters were detected in 59.5% (125/210) and in 5% (3/61) of the malignant and benign cases, respectively, although it was not detected in normal individuals 0% (c 2 ¼ 47.79, P < 0.0001; Table 2 ). For early bladder cancer detection, receiver operating characteristic curve (ROC) was plotted for the discrimination between malignant and nonmalignant groups by using RARb 2 and APC (Fig. 2) . Multivariate MANOVA revealed statistical significant effect of investigated methylated RARb 2 and APC genes, and cytology on diagnosis of bladder cancer (F ¼ 55.916, Wilks' 
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Lambda ¼ 0.456 at P < 0.0001), the test between subject effect revealed significant efficacy of RARb 2 and APC genes (F ¼ 31.9, 73.3, and 53.5, respectively, at P < 0.0001) and superiority to cytology as diagnostic markers (F ¼ 53.5 at P ¼ 0.002). Considering bilharzial status among the enrolled patients collectively, methylation of RARb 2 and APC promoters were significantly higher in patients (benign vs. malignant) with bilharzial infection as compared with those with no bilharzial infection. Bilhariziasis was associating 50% (5/10) and 100% (3/3) of methylated RARb 2 and APC among the benign cases, and 71.2% (94/132) and 68.8% (86/125) of methylated RARb 2 and APC among the bladder cancer cases, respectively. Homoplasmic methylated (M/M) RARb 2 and APC genes were only detected in bilharzial bladder cancer. Heteroplasmic methylated (M/U) RARb 2 and APC genes were detected in 17.9% (5/28) and in 10.7% (3/28) in bilharzial benign cases (bilharzial dysplasia and bilharzial cystitis), whereas among the bilharzial bladder cancer patients, they were detected in 64.8% (83/128) for both, respectively, as shown in Table 2 .
Correlation between APC and RARb 2 promoter methylation and clinicopathologic factors in bladder cancer Methylated APC and RARb 2 promoters revealed no significant correlation with any of the clinicopathologic factors.
No statistical difference was detected between bilharizial bladder cancer and clinicopathologic factors apart from cytology. Methylated RARb 2 and APC patterns were highly expressed in bilharzial bladder cancer as compared with nonbilharzial bladder cancer, although statistical difference was not reached.
Concordance between RARb 2 , APC methylation patterns, and urine cytology
Authors have investigated the concordance between APC, RARb 2 methylation patterns, and urine cytology among the study population (n ¼ 320), as shown in Table 3 .
Overall sensitivity, specificity, PPV, NPV, and accuracy of methylated RARb 2 and APC and urine cytology All these statistical analyses were carried out to evaluate the efficiency of these urine markers to discriminate between malignant and nonmalignant groups (normal individuals and benign group), as shown in Table 4 . The sensitivities of urinary methylated RARb 2 and APC were superior to urine cytology for detection of bladder cancer, nonmuscle invasive bladder cancer (early stages), low grades, bilharzial cases, and SCC. As infection (i.e., bilhariziasis) may induce promoter methylation of certain genes; authors have investigated the diagnostic efficacy of RARb 2 and APC among those with nonbilharzial infection. Similarly, their sentitivities were superior to urine cytology (sensitivity: 76.4%, 71.4%, and 50% for RARb 2 and APC and cytology, respectively). Combination between urinary methylated RARb 2 and APC increased their sensitivity with slight decrease in their specificity except for bilharzial association, where the sensitivity increased with absolute specificity.
Discussion
Previous studies suggested that DNA methylation in urine could be useful diagnostic tests but were limited by bladder cancer type (e.g., no bilharzial bladder cancer), and inappropriate controls (e.g., no benign urological group). In this study, authors have investigated 2 DNA methylation biomarkers RARb 2 and APC (13), using MSP PCR (12) , which can distinguish cytosine from methylated cytosine residues and can detect as few as 1 to 10 tumor cells among 10 Our results revealed significant urinary APC and RARb 2 promoter hypermethylation in malignant group as compared with benign and healthy normal groups confirming previous reports (13, 23) . The DNA hypermethylation of both genes was neither stage nor grade dependent, indicating that their usefulness is not limited to high-grade or high-stage tumors. DNA methylation of APC and RARb 2 improves the sensitivity of urine cytology to 93.5%, 91.9%, and 80.9% in detecting superficial bladder cancer (nonmuscle invasive bladder cancer), low-grade tumors, and bilharzial associated bladder cancer, respectively.
Among all groups of this study, there was a positive correlation between smoking and bilharziasis (P < 0.01), which are well-known risk factors of bladder cancer (24) . Meanwhile, there was no difference between bilharzial bladder cancer and nonbilharzial bladder cancer as regard to clinicopathologic criteria (25) .
Studies proved that there is epigenetic disparity between nations. A unique profile of both environmental and genetic factors in every nation may contribute to such a geographically distinct methylation pattern. For this reason, it was important to investigate gene methylation in bilharzial bladder cancer.
To the best of our knowledge, this study is the first to investigate urinary RARb 2 and APC methylation patterns in bilharzial bladder patients in comparison with nonbilharzial cases. There was a significant difference between bilharzial benign cases (bilharzial dysplasia and bilharzial cystitis), and bilharzial malignant cases regarding methylated RARb 2 and APC; Table 2 . Interestingly, when considering bilhariziasis among benign patients (bilharzial dysplasia and bilharzial cystitis), half of them showed methylated RARb 2 , whereas all of the benign patients with methylated APC suffered from bilhariziais. Moreover, homoplasmic methylation pattern for both RARb 2 and APC was only found in bilharzial bladder cancer, indicating that bilharzial infestation might play a role in the aberrant hypermethylation underlying carcinogenesis. Thus, these findings can add to the diagnostic value of methylated RARb 2 and APC in early detection of bladder cancer.
Concordance between methylated RARb 2 and APC as well as urine cytology was investigated (Table 3) . A significant difference between them indicates that these 3 urine markers were independent and their combinations will improve their sensitivities in detecting bladder cancer.
When a urine molecular marker is used for diagnostic work-up of bladder cancer, it should have a high sensitivity (26) . Accordingly, urinary methylated RARb 2 and APC are significantly superior to urine cytology (Table 4) . Methylated urinary RARb 2 and APC were detected in 37 cases (31.1%) and 35 cases (29.4%), respectively, with negative urine cytology (n ¼ 119), signifying their values in the early diagnosis of bladder cancer. Thus, combination of RARb 2 or APC methylation with urine cytology improved the sensitivity of urine cytology. Moreover, the sensitivity of urine cytology was the highest when combined with methylated RARb 2 and APC altogether in bilharzial and nonbilharzial cases (Table 4) .
Thus, the detection of methylated RARb 2 and APC by MSP in urine sediment DNA is a powerful noninvasive approach for the detection of bilharzial and nonbilharzial bladder cancer over urine cytology. However, further multicentric studies will be required to define the impact of these molecular markers on early detection and disease monitoring before clinical application, also, longitudinal follow-up of bilharzial cases is needed to understand the association of methylation of candidate genes in cancer development.
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